In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AxoGen nets $115.6mm in FOPO

Executive Summary

AxoGen Inc. (allografts and surgical tools for peripheral nerve regeneration and repair) netted $115.6mm through the public offering of 3mm shares at $41. The company originally planned to sell 2mm shares. AxoGen will use the proceeds to support long-term tissue processing and manufacturing facilities for its products--including Avance off-the-shelf processed human nerve allograft; AxoGuard porcine submucosa extracellular matrix nerve connector; and Avive human umbilical cord soft tissue membrane--and to increase capacity.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Medical Devices
    • Biomaterials
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies